



Great
Debates
& Updates

Gastrointestinal Malignancies



Where Debate
& Discussion
Translate
to Treatment

Now offering
THREE locations

New York, NY
August 13–15
New 3-Day Format

Chicago, IL
September 25–26

Los Angeles, CA
October 23–24

Save \$50 on
registration.

Use code
GDUGI

gioncologydebates.com

HMP Global Event



Interested in Exhibiting?

This conference series offers several support opportunities that are designed to increase your companies' recognition and the opportunity to showcase your products and services to this audience of oncology professionals.

678.242.0719
exhibits@imedex.com

Compelling Arguments.

Engaging Discussions.

Practical Takeaways.



Great Debates & Updates

Gastrointestinal Malignancies

Known for its unique, debate-style format, thought leaders from the nation's leading cancer institutes meet onstage to dive into the most controversial topics shaking up the field of gastrointestinal cancer:

- Colorectal Cancers
- Emerging Concepts and Therapies in GI
- Hepatobiliary Cancers
- Immunotherapy
- Pancreatic Cancers
- Rare Tumors
- Upper GI Cancers



Meet the Chairs

Axel Grothey, MD

West Cancer Center
Memphis, Tennessee



David H. Ilson, MD, PhD

Memorial Sloan Kettering Cancer Center
New York, New York

ENDORSEMENT

The following organization endorses this conference:



SCIENTIFIC AGENDA

Day 1 | New York, Chicago, Los Angeles

1:00 PM Welcome and Introduction

Session I: Colorectal Cancers I

1:10 PM Pre-Session Audience Survey
1:20 PM Early-Onset Colorectal Cancer: A Biologically Distinct Threat?
1:40 PM Debate: FOxTROT or Not: Neoadjuvant Therapy for Locally Advanced Colon Cancer
2:00 PM The Nonoperative Management of Rectal Cancer
2:20 PM Post-Session Audience Survey
2:30 PM Expert Panel Discussion
2:50 PM Break

Session II: Colorectal Cancers II

3:20 PM How Similar are Biosimilars?
3:50 PM Debate: First-Line Treatment in Left-Sided, RAS/BRAF WT Cancer
EGFR vs VEGF
4:10 PM Debate: First-Line Therapy for BRAF V600E Targeted Triplet vs FOLFOXIRI/Bev
4:30 PM Debate: Are Biomarkers like CMS and ctDNA Ready to Direct Adjuvant Therapy
4:50 PM Debate: High-Risk Stage II Colon Cancer
3 Months of CAPOX vs 6 Months of Capecitabine
5:10 PM Expert Panel Discussion
5:30 PM Adjourn

Day 2 | New York, Chicago, Los Angeles

8:00 AM Welcome and Introduction

Session III: Pancreatic Cancer

8:10 AM Pre-Session Audience Survey
8:20 AM New Treatment Options in Pancreatic Cancer
8:50 AM Debate: Resectable Pancreatic Cancer
Total Neoadjuvant Therapy vs Adjuvant Therapy
9:10 AM Debate: Maintenance Therapy in BRCA+ Pancreatic Cancer
PARP Inhibitor vs Continued Chemotherapy
9:30 AM Post-Session Audience Survey
9:40 AM Expert Panel Discussion
9:50 AM Break

Session IV: Hepatobiliary Cancers

10:20 AM Pre-Session Audience Survey
10:30 AM Novel and Targeted Therapies in Biliary Cancer
11:00 AM Debate: Optimal First-Line Therapy for HCC
VEGF-Targeted Therapy vs Checkpoint Inhibitor
11:20 AM Management of Adverse Events With Immunotherapy
11:40 AM Novel Agents and Targets in HCC
12:10 PM Locoregional Treatment Approaches: When to Use and When Not to Use
12:30 PM Post-Session Audience Survey
12:40 PM Expert Panel Discussion

SCIENTIFIC AGENDA

12:50 PM Lunch

Session V: Targeted Approaches in Gastric Cancers and Other GI Malignancies

1:50 PM Pre-Session Audience Survey
2:00 PM Current Positioning of Immunotherapy in Gastroesophageal Cancer
2:20 PM Novel Non-Immunotherapy Targets and Agents in Gastroesophageal Cancer
2:40 PM Novel Agents and Targets in Colorectal Cancer
3:10 PM Debate: TNT for Rectal Cancer
Short-Course Radiation Therapy vs Long-Course Radiation Therapy
3:30 PM Debate: Comprehensive Molecular Panel Testing in GI Cancers
A Waste of Resources vs Mandatory for All Metastatic GI Cancers
3:50 PM Post-Session Audience Survey
4:00 PM Break

Session VI: Gastroesophageal Cancer

4:30 PM Debate: Ablative Therapies for Oligometastatic Disease
Fact vs Fiction
4:50 PM Debate: Esophageal and GEJ Cancers
CROSS vs FLOT
5:10 PM Debate: Adjuvant Therapy in Biliary Cancers:
Capecitabine Standard Therapy
5:30 PM Adjourn

Day 3 | New York Only*

8:00 AM Welcome and Introduction

Session VII: Gastrointestinal Cancer: Emerging Concepts and Therapies

8:10 AM Genetics in GI Cancers
8:30 AM Circulating Tumor DNA: Emerging Role in Adjuvant and Advanced Disease Therapy
9:00 AM Molecular Tumor Board: Case Presentations on Clinical Implications of Next-Generation Sequencing in Different Tumor Types
9:30 AM Expert Panel Discussion
9:50 AM Break

Session VIII: Rare Tumors

10:20 AM Novel Agents and Approaches in NETs
10:50 AM Debate: SURFs Up: Early HCC
Surgery vs Ablative Therapy
11:10 AM Debate: Optimal Second-Line Therapy in pNET
Cape/Tem vs PRRT
11:30 AM Expert Panel Discussion
12:00 PM Adjourn

*
New York will
be the only
3-day series.

The entire agenda
will be presented
at all locations.

Agenda and
Faculty are subject
to change. Please
visit the website
for the latest
conference
details.

2020 Faculty*

*Includes confirmed and invited speakers.

Ghassan K. Abou-Alfa, MD, MBA
Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Al B. Benson, III, MD, FACP, FASCO
Professor
Feinberg School of Medicine
Northwestern Medicine
Chicago, Illinois

Jordan D. Berlin, MD
Ingram Professor of Cancer Research
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee

Mitesh J. Borad, MD
Associate Professor of Medicine
Mayo Clinic
Phoenix, Arizona

Daniel Catenacci, MD
Associate Professor of Medicine
UChicago Medicine
Chicago, Illinois

Andrea Cercak, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Michael A. Choti, MD
Chief of Surgery, Banner MD
Anderson Cancer Center
Mesa, Arizona

Christopher H. Crane, MD
Vice Chairman, Memorial Sloan Kettering Cancer Center
New York, New York

Jennifer Eads, MD
Associate Professor of Medicine
Abramson Center for Advanced Medicine
University of Pennsylvania
Penn Medicine
Philadelphia, Pennsylvania

Cathy Eng, MD, FACP, FASCO
Sophie Caroline Steves Distinguished Professorship in Cancer Research
Vanderbilt-Ingram Cancer Center
MD Anderson Cancer Center
Nashville, Tennessee

Axel Grothey, MD
Director, GI Cancer Research
West Cancer Center
Germantown, Tennessee

Howard S. Hochster, MD
Associate Cancer Center Director
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

David H. Ilson, MD, PhD
Professor of Medicine
Weill Cornell Medical College
Memorial Hospital
Memorial Sloan Kettering Cancer Center
New York, New York

Milind Javle, MD
Professor of Medicine
MD Anderson Cancer Center
The University of Texas
Houston, Texas

Pashtoon M. Kasi, MD, MS
Assistant Professor
College of Medicine/
Oncology
University of Iowa
Iowa City, Iowa

Scott Kopetz, MD, PhD
Associate Professor
MD Anderson Cancer Center
The University of Texas
Houston, Texas

Geoffrey Y. Ku, MD
Head, Esophagogastric Section
Memorial Sloan Kettering Cancer Center
New York, New York

Eileen M. O'Reilly, MD
Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Rachna Shroff, MD, MS
Associate Professor of Medicine
University of Arizona Cancer Center
Tucson, Arizona

Zsafia K. Stadler, MD
Associate Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Jonathan R. Strosberg, MD
Professor
Moffitt Cancer Center
Tampa, Florida

Nataliya Uboha, MD, PhD
Assistant Professor of Medicine
University of Wisconsin
Madison, Wisconsin

Noam A. VanderWalde, MD, MS
Associate Professor and Director of Clinical Research
West Cancer Center and Research Institute
University of Tennessee Health Science Center
Memphis, Tennessee

Faculty are subject to change. Please visit the website for the latest conference details.

WHO SHOULD ATTEND

This live educational activity is designed to meet the educational needs of those who are involved and/or interested in the treatment of patients with GI cancers.

Community Oncologists
Physicians
Physician Assistants

Physicians-in-Training
Oncology Nurses
Pharmacists

GROUP DISCOUNTS

Available for attendees from the same practice!

CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statements: Physicians: This activity has been approved for *AMA PRA Category 1 Credit(s)*™.

Nurses: This continuing nursing education activity has been approved to offer continuing contact hours for nurse professionals. This activity will also award pharmacotherapeutic contact

hours. Final designation of these hours will be provided upon final review of the conference agenda.

Pharmacy: This live, knowledge-based activity has been approved to offer continuing education units (CEUs) for pharmacists.

Learning Objectives: Upon completion of this activity, participants should be better able to:

- Analyze the mechanism of action (MOA) and safety-efficacy profiles of currently approved and emerging oncological agents including immunotherapies for the management of GI malignancies
- Integrate clinical trial data and evidence-based therapies for improving clinical outcomes in patients with GI malignancies
- Evaluate the best practices and standards of care based on a multidisciplinary approach for the management of GI cancers
- Implement the rational use of immunotherapies in patients with GI malignancies on a case-by-case basis
- Define patient populations most suitable for enrolling in GI clinical trials for progressive advanced-stage GI malignancies
- Implement optimal management strategies for both metastatic and non-metastatic GI malignancies based on personalized factors such as comorbidities, cost, disease stage, and prior therapeutic regimens

More Locations, Education, and Value.

WAYS TO REGISTER

Online: gioncologydebates.com

Phone: 800.233.0957

International: 678.242.0906

Email: registration@imedex.com

Use code **GDUGI** to save \$50 on registration!

REGISTRATION RATES	EARLY	REGULAR
Physician/PhD/Pharm	\$279	\$329
PA/NP	\$169	\$199
Nurse/Student/Resident/Fellow	\$89	\$99
Industry	\$549	\$549

REGISTRATION CUTOFF REMINDERS:

New York, NY
2/28/20

Chicago, IL
8/21/20

Los Angeles, CA
9/10/20



New York Marriott Marquis

Special Room Rate

\$349

per night, plus tax.

1535 Broadway
New York, NY
10036




Chicago Marriott Magnificent Mile

Special Room Rate

\$215

per night, plus tax.

540 N Michigan Ave
Chicago, IL
60611



Marina Del Ray Marriott

Special Room Rate

\$239

per night, plus tax.

4100 Admiralty Way
Marina del Rey, CA
90292

Enroll in the **Great Debates & Updates Value Package** and save by signing up for multiple locations at once!

Visit the meeting website to book these special event rates.



Great
Debates
& Updates

Gastrointestinal
Malignancies

MEDEX

AN HMP COMPANY

11675 Rainwater Drive, Suite 600, Alpharetta, GA 30009, USA

Where Debate & Discussion Translate to Treatment

NOW OFFERING THREE LOCATIONS

August 13–15, 2020 | **3 Days!**
New York, NY

September 25–26, 2020
Chicago, IL

October 23–24, 2020
Los Angeles, CA

Save \$50 on registration by using code **GDUGI**.
gioncologydebates.com